A drug of Hainan General Sanyo Pharmaceutical, a unit of China Meheco Group (SHA:600056), is expected to be selected in China's centralized drug procurement bid after being included in the list, according to a Shanghai Stock Exchange disclosure on Saturday.
The drug, piperacillin sodium for injection, is used to treat patients with sepsis and other bodily infections. The pharmaceutical company proposed a bid of 2.27 yuan per piece for the drug.
Drugs selected in the centralized bidding will be prioritized by medical institutions in the country during the procurement cycle, the disclosure said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments